These are the key messages that translate InBody results into actionable, motivating guidance for patients on semaglutide therapy
These include: Orlistat : A lipase inhibitor that reduces fat absorption, with a different mechanism and side effect profile than appetite suppressants Naltrexone-bupropion : A combination medication affecting reward pathways and appetite regulation Phentermine-topiramate ER (Qsymia) : An FDA-approved combination that has been studied more extensively than phentermine-semaglutide and is approved for long-term use Tirzepatide (Zepbound) : A dual GIP/GLP-1 receptor agonist that has demonstrated greater weight loss than semaglutide in head-to-head clinical trials (SURMOUNT-5) Intensive lifestyle interventions remain foundational to successful weight management
For injectables, you need a cooler bag with ice packs that maintains proper temperature for the duration of travel
What works for you may not work for everyone else, so trust in your prescriber and take their advice.
These contribution limits provide sufficient room to cover multiple months of GLP-1 therapy while retaining flexibility for other qualified medical expenses like office visits, lab work, or genetic testing through PlexusDx's Precision Peptide assessment
Most people experience initial appetite suppression within 37 days of their first injection, though the timeline and intensity vary based on individual biology
